Epidarex Portfolio News

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY


Category: Epidarex Portfolio News

Apellis Pharmaceuticals Announces Formation of Scientific Advisory Board

Crestwood, KY – July 15, 2015 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the formation of a Scientific Advisory Board (SAB) comprised of physicians and scientists recognized as key opinion leaders in the areas of immunology, pulmonology, ophthalmology and hematology….

Therapeutic Thought – Complement Immunotherapy

Apellis’ CEO, Cedric Francois, outlines the company thoughts regarding the emergence of immunotherapy as a therapeutic approach that focuses on correcting the underlying immune dysregulation rather than addressing the symptoms of a conditions.  In particular, the article discusses how the complement system plays a key role…

Five Questions with Bill Niland, Harpoon Medical CEO

By Scott Dance, The Baltimore Sun Within a year and a half of launching as a startup, Harpoon Medical’s heart surgery device could be used on humans for the first time in a matter of weeks. The Kent Island-based company expects doctors in Poland to…